Why grade 4 cartilage damage doesn't automatically rule out injection treatment

Grade 4 (ICRS/Outerbridge) cartilage loss is often presented to patients as a crossroads: reconstruct surgically or replace the joint. In practice, the picture is more nuanced.

ChondroFiller® (Meidrix Biomedicals GmbH, Germany) is a CE-marked Class III acellular Type I collagen scaffold whose formal CE indication explicitly covers Grade III and Grade IV lesions in the knee — including full-thickness defects where subchondral bone is exposed. That explicit coverage matters: it places grade 4 knees within the product's licensed range rather than at its margins.

In the current clinical pathway, ChondroFiller is delivered as an ultrasound-guided injection at an outpatient appointment — no general anaesthetic, no theatre admission, no surgical incisions. Once placed into the defect zone, the collagen matrix gels in situ within three to five minutes, forming a stable three-dimensional scaffold. That scaffold creates a structural environment that draws in the patient's own progenitor cells from the surrounding synovium and subchondral bone — a process described as acellular matrix-induced chondrogenesis. No prior cell biopsy is needed, and no microfracture bone drilling is required.

Grade 4 alone is not an exclusion. Whether a particular patient with grade 4 loss is a realistic candidate depends on the pattern of the defect, the condition of the surrounding joint, and the mechanical environment of the knee — the factors that the sections below address in turn.

Two candidacy pathways: focal defect versus diffuse joint-surface loss

The single most important question at assessment is not how severe the damage is, but how it is distributed.

A single worn patch in an otherwise reasonable joint

Some grade 4 patients have a discrete, bounded area of full-thickness loss — a contained defect, typically up to 6 cm², sitting within a joint where the surrounding cartilage is still largely intact. This is the focal defect pathway. Here, the collagen scaffold fills and bridges the lesion from its base upward, anchoring against healthy cartilage at the edges. The surrounding tissue acts as a biological border that supports integration. The regenerative evidence is strongest for this group: published knee studies report IKDC scores rising by approximately 30 points at three years, and MOCART MRI scores between 70 and 87 out of 100 at one year.

Wear spread across most of the joint surface

Other grade 4 patients — including those with Kellgren-Lawrence Grade III or IV disease, sometimes described as 'bone on bone' — present with more diffuse surface loss affecting a broader area. For these patients, the injectable scaffold works differently: it is placed as a viscoelastic top-down coating over the irregular worn surface rather than rebuilding a specific defect from below. This cushioning layer also promotes the body's own endogenous repair processes, but it is not a claim of full cartilage restoration. Expectations for this group should reflect that distinction.

Neither pathway imposes a formal upper age limit or defect-size ceiling — a meaningful difference from surgical options such as ACI, microfracture, or osteochondral grafting, which carry stricter anatomical criteria.

Determining which pathway applies requires detailed imaging. MRI with cartilage-specific sequencing — and cartilage segmentation where available — maps defect size, depth, and surrounding tissue quality before any treatment plan is confirmed.

Who is excluded and who needs pre-correction first

Not every grade 4 knee qualifies — and working through the exclusion logic clarifies exactly what a candidacy consultation is designed to evaluate.

Absolute contraindications

A small number of conditions rule out ChondroFiller® entirely, irrespective of defect pattern or size:

• Active inflammatory arthritis — for example, rheumatoid arthritis in flare — where the joint environment actively undermines scaffold integration
• Active malignancy
• Known allergy to collagen or rat-derived proteins
• End-stage tricompartmental osteoarthritis where total knee replacement is already the clinically appropriate decision

That last point deserves specific attention for grade 4 patients. When full-thickness loss is so extensive and the biological environment so depleted that the joint cannot support endogenous repair, an injectable scaffold is not an appropriate substitute for joint replacement. A structured consultation is designed to separate this group from those who remain realistic candidates — the distinction is not always self-evident from symptoms alone.

Relative exclusions: correctable before proceeding

Some mechanical problems do not permanently disqualify a patient, but they require resolution before injection proceeds:

• Malalignment greater than 5° (varus or valgus) — uneven loading concentrates stress on the scaffold before integration is complete
• Ligament instability — an unsupported knee shifts abnormally under load, preventing the scaffold from settling correctly
• Significant meniscal deficiency — the meniscus distributes compressive force across the tibial surface; its absence alters loading throughout the joint

In each case, a corrective procedure — osteotomy for malalignment, ligament reconstruction for instability — may be undertaken first, with ChondroFiller considered as a subsequent step once the mechanical environment is stable. These corrections are separate clinical pathways, not components of the injection treatment itself.

What the clinical evidence shows at grade 4 level

Published outcomes for ChondroFiller® in the knee are encouraging, but they carry a qualification that changes how the numbers should be read. The functional gains reported in cohort studies — including the IKDC and MOCART improvements discussed in the previous section — reflect carefully selected patient populations, not unscreened grade IV presentations. The 70–85% rate of meaningful symptom and function improvement at three to five years applies to patients who met the candidacy criteria across all four assessment dimensions; it should not be read as a general prediction for anyone presenting with full-thickness cartilage loss.

The strongest available comparison of cartilage tissue quality comes from Demmer et al. (2025), published in PMC. At follow-up arthroscopy, ChondroFiller-treated defects showed significantly superior cartilage scores compared with controls — median Outerbridge 1.5 versus 3.0 (P=0.006) and ICRS grade 1 versus 3 (P=0.002). The same study found that fibrous tissue formation occurred only in overfilled defects; cases where the scaffold was applied flush with the surrounding surface were free of it. That technical detail matters: how the product is applied influences what the tissue produces.

At a mechanistic level, a 2025 ex vivo osteochondral model demonstrated a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14 — confirming that the scaffold actively recruits host cells rather than passively occupying space and supports the body's own repair processes.

Two evidence gaps deserve direct acknowledgement. No large randomised controlled trial is available that is specific to grade IV knee defects. The focal defect pathway also has a more established evidence base than the diffuse osteoarthritis route, where the rationale for using the scaffold as a top-down cushion rests on smaller and less mature data. These gaps are not reasons for alarm — they are the reason that structured candidacy assessment, rather than grade alone, determines whether treatment is appropriate.

How candidacy is assessed in practice

Three strands of information converge at a candidacy appointment: the patient's clinical history, weight-bearing imaging, and detailed MRI of the knee.

The history covers symptom duration and trajectory, prior treatments, activity demands, and any systemic conditions — particularly autoimmune or inflammatory disease — that bear on the joint's biological environment. Weight-bearing X-ray provides Kellgren-Lawrence grading to characterise joint-space loss across compartments, distinguishing a single-compartment problem from the tricompartmental picture that moves a patient towards joint replacement rather than scaffold treatment.

MRI carries the most clinical weight in pathway mapping. Defect size, border quality, subchondral bone condition, and the health of the surrounding articular surface together determine whether a lesion qualifies as focal and contained, and whether the tissue environment can support scaffold integration. It is this combination — not grade alone — that separates the focal defect pathway from the diffuse OA pathway described earlier in this article.

Biomechanical assessment adds the mechanical dimension. Lower-limb alignment and gait analysis can reveal malalignment or loading asymmetry subtle enough to escape standard clinical examination but significant enough to stress a scaffold before integration is complete.

Clinics offering structured assessment for this pathway — including Lincolnshire Knee — may supplement these steps with objective tools: onMRI™ provides AI-assisted cartilage and meniscus segmentation with T2 mapping, while MAI Motion® captures objective gait and loading patterns, both of particular value when alignment is a borderline concern rather than a clear-cut finding.

Access, costs, and next steps for UK patients

ChondroFiller® is not NHS-funded and is not currently covered by major UK private insurers. The only available route for UK patients is self-funded private treatment. Guide costs run from approximately £3,000 to £8,000 depending on the number of boxes required and clinical complexity; patients should confirm the guide cost for their specific case directly with the treating clinic before booking.

For patients who have encountered the product through international research: ChondroFiller® is CE-marked and available across Europe and the UK, but it is not FDA-approved in the United States — a factual distinction rather than a clinical one for most UK patients.

An assessment appointment is the appropriate first step. Candidacy cannot be established remotely or from an existing scan report alone. Which pathway applies — and whether the joint environment can support the scaffold — requires direct clinical evaluation and imaging review specific to the individual knee.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral and without NHS waiting lists. Consultations are available in Sleaford (NG34) and Grantham (NG31). Grade 4 cartilage loss is a realistic starting point for that conversation — the assessment exists to establish what options remain open, not to confirm assumptions formed before the joint has been properly evaluated. To find out whether you remain a candidate, book an assessment at lincolnshireknee.co.uk.